Hein A. W. van Onzenoort

Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment

Hein A. W. van Onzenoort, Frederique E. Menger, Cees Neef et al. · Hypertension · 2011 · 127 citations · Full text

Pharmacy, Chronic Disease Control, Clinical Pharmacy +14

Assessing Medication Adherence Simultaneously by Electronic Monitoring and Pill Count in Patients With Mild-to-Moderate Hypertension

Hein A. W. van Onzenoort, W. J. Verberk, A. G. H. Kessels et al. · American Journal of Hypertension · 2009 · 78 citations · Full text

Pharmacy, Clinical Pharmacy, Health Informatics +17

Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis

Johanna H. M. Driessen, Ronald M.A. Henry, Hein A. W. van Onzenoort et al. · Calcified Tissue International · 2015 · 75 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs

Johanna H. M. Driessen, Hein A. W. van Onzenoort, Jakob Starup‐Linde et al. · Calcified Tissue International · 2015 · 73 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture

Johanna H. M. Driessen, Hein A. W. van Onzenoort, Ronald M.A. Henry et al. · Bone · 2014 · 68 citations

Medicine, Pharmacology, Pharmacotherapy +11